PMID- 31446304
OWN - NLM
STAT- MEDLINE
DCOM- 20200504
LR  - 20200505
IS  - 1879-3320 (Electronic)
IS  - 0960-7404 (Linking)
VI  - 31
DP  - 2019 Dec
TI  - Clinical management of malignant ovarian germ cell tumors: A 26-year experience 
      in a tertiary care institution.
PG  - 8-13
LID - S0960-7404(19)30182-3 [pii]
LID - 10.1016/j.suronc.2019.08.006 [doi]
AB  - BACKGROUND: The standard prognostic system for malignant ovarian germ cell tumors 
      (MOGCT) has not yet been established and the scope of surgery was also 
      controversial. Mixed ovarian malignant germ cell tumor (mGCT) is a rare 
      histological type of MOGCT with higher malignant degree than other types. The aim 
      of the present study was to investigate the clinical features and prognosis of 
      mGCT, and prognostic factors for MOGCT to provide guidance for future treatment. 
      METHODS: Retrospective analysis was carried out on 137 patients, who were 
      admitted from 1991 to 2014. Survival curves were constructed using Kaplan-Meier 
      method and were compared with the log-rank test across various pathological types 
      and different stages. Multivariate survival analysis was performed using Cox's 
      proportional hazards model. RESULTS: There were 29 dysgerminomas (DG), 3 
      embryonal carcinomas (EC), 43 immature teratomas (IT), 48 yolk sac tumors (YST) 
      and 14 mixed germ cell tumors (mGCT). The most common type of mGCT is YST 
      (85.7%), followed by IT (64.3%), EC (28.6%), and DG (21.4%). The respective 
      5-year OS rates were 100% in DG, 100% in EC, 92.5% in IT, 54.5% in YST and 66.7% 
      in mGCT, while the corresponding 5-year PFS rate were 89.7% in DG, 100% in EC, 
      85.1% in IT, 55.9% in YST and 60% in mGCT. FIGO stage Ⅲ-Ⅳ, certain pathological 
      types (Yolk sac tumors and mGCT) and the number of postoperative chemotherapy 
      courses were independently unfavorable prognostic in a multivariate model that 
      included age, Admission decade, fertility-sparing surgery, and comprehensive 
      staging surgery. CONCLUSIONS: Fertility-sparing surgery and incomplete surgical 
      staging did not affect the prognosis. It might be safe to preserve fertility and 
      shrink the scope of the surgical procedures in MOGCT patients regardless of stage 
      or pathology. However, prospective randomized controlled trials were needed for 
      further evaluation.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Hu, Ting
AU  - Hu T
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, People's Republic of China.
FAU - Fang, Yong
AU  - Fang Y
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, People's Republic of China.
FAU - Sun, Qian
AU  - Sun Q
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, People's Republic of China.
FAU - Zhao, Haiyue
AU  - Zhao H
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, People's Republic of China.
FAU - Ma, Ding
AU  - Ma D
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, People's Republic of China.
FAU - Zhu, Tao
AU  - Zhu T
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, People's Republic of China. 
      Electronic address: zhutao@tjh.tjmu.edu.cn.
FAU - Wang, Changyu
AU  - Wang C
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, People's Republic of China. 
      Electronic address: wangchangyutjh@163.com.
LA  - eng
PT  - Journal Article
DEP - 20190820
PL  - Netherlands
TA  - Surg Oncol
JT  - Surgical oncology
JID - 9208188
RN  - Ovarian Germ Cell Cancer
SB  - IM
EIN - Surg Oncol. 2019 Oct 25;32:1. PMID: 31669815
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy
MH  - Disease Management
MH  - Female
MH  - *Fertility Preservation
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Neoplasms, Germ Cell and Embryonal/pathology/*therapy
MH  - Ovarian Neoplasms/pathology/*therapy
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Tertiary Healthcare/*statistics & numerical data
MH  - Time Factors
MH  - Young Adult
OTO - NOTNLM
OT  - Chemotherapy
OT  - Fertility-sparing surgery
OT  - Malignant germ cell tumor
OT  - Ovarian neoplasms
OT  - Prognosis
EDAT- 2019/08/26 06:00
MHDA- 2020/05/06 06:00
CRDT- 2019/08/26 06:00
PHST- 2019/04/24 00:00 [received]
PHST- 2019/07/17 00:00 [revised]
PHST- 2019/08/20 00:00 [accepted]
PHST- 2019/08/26 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
PHST- 2019/08/26 06:00 [entrez]
AID - S0960-7404(19)30182-3 [pii]
AID - 10.1016/j.suronc.2019.08.006 [doi]
PST - ppublish
SO  - Surg Oncol. 2019 Dec;31:8-13. doi: 10.1016/j.suronc.2019.08.006. Epub 2019 Aug 
      20.